Besides, our study suggests that GDP mobilization regimen may be more effective in HL patients in comparison to NHL patients in terms of premobilization PLT levels, PB CD34+ stem cell counts, first-day collected stem cell amount of the mobilization, and the total number of CD34+ stem cells collected as shown in Tables 6 and 7. The gene discussed is CD34; the disease is non-Hodgkin lymphoma.